Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Current Investments (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash & Current Investments for 16 consecutive years, with $65.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments fell 82.19% to $65.5 million in Q3 2025 year-over-year; TTM through Mar 2025 was $258.1 million, a 44.33% decrease, with the full-year FY2024 number at $292.9 million, up 153.15% from a year prior.
  • Cash & Current Investments was $65.5 million for Q3 2025 at Standard Biotools, down from $78.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $463.6 million in Q1 2024 to a low of $29.5 million in Q4 2021.
  • A 5-year average of $168.7 million and a median of $143.1 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: soared 565.73% in 2022, then tumbled 82.19% in 2025.
  • Standard Biotools' Cash & Current Investments stood at $29.5 million in 2021, then surged by 466.05% to $166.8 million in 2022, then crashed by 30.64% to $115.7 million in 2023, then surged by 153.15% to $292.9 million in 2024, then tumbled by 77.64% to $65.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash & Current Investments are $65.5 million (Q3 2025), $78.5 million (Q2 2025), and $258.1 million (Q1 2025).